Trigyn Techno. (TRIGYN)

Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At ₹58.44, Trigyn trades just below its book value of ₹59.43 — that catches my Graham eye. With debt/equity of only 0.01, there is no balance-sheet pressure; the company can survive even if operations stumble. But survival is not enough. The latest quarter shows ₹258 crore of revenue converting into just ₹1 crore of net profit. Such a thin margin tells me this is a low-pricing-power IT services/consulting business, not a franchise with pricing power. Reported ROE is -2.48%, and ROCE is just 4.17%, well below what I demand for deploying capital. The P/E of 29.93 is therefore a premium for hopes, not for current earning quality. What looks better? Sales grew 24.78% and profit grew 26.02%; the Piotroski F-score of 7/9 implies improvements in profitability, leverage and efficiency. Promoter holding of 44.51% gives some comfort that owner and minority interests are roughly aligned. With PEG around 1.18, the growth is not absurdly priced if the 26% profit growth is durable. But "if" is the key word. Zero dividend yield means I receive nothing while waiting for the story to play out. Mr. Market has already cut the price from ₹102.40 to ₹58.44. At near book value, the asset cushion limits some downside, but the real return depends on turning these thin margins into a healthy, positive ROE. This is a potential turnaround, not a stalwart. I want to see at least a few quarters of respectable net margins, positive and improving ROE, and cash generation before committing. The balance sheet gives me patience, but only evidence of a genuinely better business will give me conviction.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer